<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR83">
 <label>83.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Howard</surname>
    <given-names>JF</given-names>
   </name>
   <name>
    <surname>Utsugisawa</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Benatar</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Murai</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Barohn</surname>
    <given-names>RJ</given-names>
   </name>
   <name>
    <surname>Illa</surname>
    <given-names>I</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study</article-title>
  <source>Lancet Neurol</source>
  <year>2017</year>
  <volume>16</volume>
  <fpage>976</fpage>
  <lpage>986</lpage>
  <?supplied-pmid 29066163?>
  <pub-id pub-id-type="pmid">29066163</pub-id>
 </element-citation>
</ref>
